Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer

Ambry Genetics300 enrolled

Overview

The primary objective of the study will be to estimate the prevalence of germline mutations in patients who present consecutively within 12 weeks of a confirmed diagnosis of pancreatic ductal adenocarcinoma.

The proposed research is a multi-site prospective and observational plan to investigate the prevalence of germline mutations in patients diagnosed with pancreatic cancer. Thirty two genes will be analyzed, all of which have been associated with an increased risk for cancer. The genes are included on CancerNextTM a multi-gene next generation sequencing and array CGH test. The 32 genes include: APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, BMPR1A, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, GREM1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMAD4, SMARCA4, STK11, and TP53 .

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

Multi-gene Next Generation Sequencing PanelGENETIC

Participants will have genetic testing

Eligibility

Sex: ALLMin age: 18 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female patients between the ages of 18 and 89 years of age. * Diagnosed within the previous 12 weeks with histologically or cytologically confirmed PDAC Stage I to IV. * Ability of participant to understand and the willingness to sign a written informed consent document. * Participant must agree to sample collection and genetic testing using the 32 gene test, CancerNextTM and allow the test result to be part of their medical record. Exclusion Criteria: * Diagnosed with intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, pancreatic neuroendocrine tumors or dysplasia without PDAC. * Diagnosed with PDAC more than 12 weeks before presenting to the clinical site. * Patients meeting the above enrollment criteria who have had CancerNext performed previously.

Locations (3)

HonorHealth Research Institute

Scottsdale, Arizona, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Outcomes

Primary Outcomes

Germline Mutation Prevalence

The primary objective of the study will be to estimate the prevalence of germline mutations in patients who present consecutively to the clinical site within 12 weeks of a histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma.

Time frame: 18 months

Secondary Outcomes

Associate age at diagnosis with germline mutation status and family history

Time frame: 18 months

Access the psychological impact of testing for hereditary pancreatic cancer

A previously validated questionnaire, the Multidimensional Impact of Cancer Risk Assessment (MICRA) will be used as a measure of the psychological impact of genetic testing.

Time frame: 18 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.